4f4c837的个人主页 - 老虎社区

4f4c837

暂无个人介绍

IP属地：未知

18关注

0粉丝

0主题

0勋章

2021-12-22

Interesting

Stocks trade mixed after rally, with tech under pressure

2021-12-22

Interesting

Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’

2021-12-22

Interesting

抱歉，原内容已删除

2021-12-22

Interesting

抱歉，原内容已删除

2021-12-22

Interesting

10 Biggest Price Target Changes For Wednesday

2021-12-22

Interesting

Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089174425482880","uuid":"4089174425482880","gmtCreate":1626139762421,"gmtModify":1640189757944,"name":"4f4c837","pinyin":"meowier","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":691625975,"gmtCreate":1640186032395,"gmtModify":1640186032395,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691625975","repostId":"2193192429","repostType":4,"repost":{"id":"2193192429","kind":"news","pubTimestamp":1640185620,"share":"https://www.laohu8.com/m/news/2193192429?lang=&edition=full","pubTime":"2021-12-22 23:07","market":"us","language":"en","title":"Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192429","media":"Bloomberg","summary":" -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.These forces have thrown the broad investment outlook for the start of 2022 into flux, but what has","content":"<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.</p>\n<p>Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.</p>\n<p>These forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.</p>\n<p>The 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.</p>\n<p>“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”</p>\n<p>Netflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.</p>\n<p>Shares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.</p>\n<p>Cahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> content, subscriber growth and margin expansion -- the longstanding yardsticks for the company -- &nbsp;will remain the catalysts for shares, he said.</p>\n<p>“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”</p>\n<p><b>Fierce Competition</b></p>\n<p>For Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&amp;P 500 Index after buying shares in September.</p>\n<p>Netflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&amp;P 500 Communication Services Index at 19.6 times.</p>\n<p>Disney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.</p>\n<p>Both Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&amp;T Inc.’s WarnerMedia, according to <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “<a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.</p>\n<p>But ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”</p>\n<p>“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.</p>\n<p><b>Buying Opportunities</b></p>\n<p>Selloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.</p>\n<p>Klink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.</p>\n<p>“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with...</p>\n\n<a href=\"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4524":"宅经济概念","BK4532":"文艺复兴科技持仓","BK4527":"明星科技股","BK4551":"寇图资本持仓","BK4566":"资本集团","NFLX":"奈飞","BK4534":"瑞士信贷持仓","BK4108":"电影和娱乐","QNETCN":"纳斯达克中美互联网老虎指数","BK4548":"巴美列捷福持仓","BK4507":"流媒体概念","DIS":"迪士尼"},"source_url":"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193192429","content_text":"(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.\nThese forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.\nThe 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.\n“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”\nNetflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.\nShares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.\nCahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. Popular content, subscriber growth and margin expansion -- the longstanding yardsticks for the company --  will remain the catalysts for shares, he said.\n“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”\nFierce Competition\nFor Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&P 500 Index after buying shares in September.\nNetflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&P 500 Communication Services Index at 19.6 times.\nDisney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.\nBoth Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&T Inc.’s WarnerMedia, according to Macquarie analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “one of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.\nBut ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”\n“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.\nBuying Opportunities\nSelloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.\nKlink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.\n“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.","news_type":1,"symbols_score_info":{"DIS":0.6,"NFLX":0.9,"QNETCN":0.9}},"isVote":1,"tweetType":1,"viewCount":1790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622121,"gmtCreate":1640185928643,"gmtModify":1640185971826,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622121","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":1568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622066,"gmtCreate":1640185916183,"gmtModify":1640185916183,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622066","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<ul>\n <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AGCO":"爱科集团","PCAR":"帕卡","ED":"爱迪生联合电气","ALXO":"ALX Oncology Holdings","FDS":"辉盛研究系统","CGNT":"Cognyte Software Ltd.","CMRX":"Chimerix Inc.","BIIB":"渤健公司","NKE":"耐克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"ADGI":0.9,"AGCO":0.9,"ALXO":0.9,"BIIB":0.9,"CGNT":0.9,"CMRX":0.9,"ED":0.9,"FDS":0.9,"NKE":0.9,"PCAR":0.9}},"isVote":1,"tweetType":1,"viewCount":2245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626406,"gmtCreate":1640185907845,"gmtModify":1640185907845,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626406","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":1365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626231,"gmtCreate":1640185895252,"gmtModify":1640185895301,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691626231","repostId":"1157274137","repostType":4,"repost":{"id":"1157274137","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640183410,"share":"https://www.laohu8.com/m/news/1157274137?lang=&edition=full","pubTime":"2021-12-22 22:30","market":"us","language":"en","title":"Stocks trade mixed after rally, with tech under pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1157274137","media":"Tiger Newspress","summary":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra","content":"<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p>\n<p>With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p>\n<p>Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p>\n<p>\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p>\n<p>\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p>\n<p>Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p>\n<p>\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p>\n<p>During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks trade mixed after rally, with tech under pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks trade mixed after rally, with tech under pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p>\n<p>With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p>\n<p>Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p>\n<p>\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p>\n<p>\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p>\n<p>Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p>\n<p>\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p>\n<p>During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157274137","content_text":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&P 500, Dow and Nasdaq opened in slightly negative territory.\nWith trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.\nOmicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests to Americans for free beginning next month.\n\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"\n\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"\nOther strategists agreed that investors should brace for more choppiness heading into the end of the year.\n\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"\nDuring a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626151,"gmtCreate":1640185863507,"gmtModify":1640185863507,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626151","repostId":"2193419144","repostType":4,"isVote":1,"tweetType":1,"viewCount":2500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":691626231,"gmtCreate":1640185895252,"gmtModify":1640185895301,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691626231","repostId":"1157274137","repostType":4,"repost":{"id":"1157274137","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640183410,"share":"https://www.laohu8.com/m/news/1157274137?lang=&edition=full","pubTime":"2021-12-22 22:30","market":"us","language":"en","title":"Stocks trade mixed after rally, with tech under pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1157274137","media":"Tiger Newspress","summary":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra","content":"<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p>\n<p>With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p>\n<p>Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p>\n<p>\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p>\n<p>\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p>\n<p>Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p>\n<p>\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p>\n<p>During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks trade mixed after rally, with tech under pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks trade mixed after rally, with tech under pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p>\n<p>With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p>\n<p>Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p>\n<p>\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p>\n<p>\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p>\n<p>Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p>\n<p>\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p>\n<p>During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157274137","content_text":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&P 500, Dow and Nasdaq opened in slightly negative territory.\nWith trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.\nOmicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests to Americans for free beginning next month.\n\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"\n\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"\nOther strategists agreed that investors should brace for more choppiness heading into the end of the year.\n\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"\nDuring a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":1814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691625975,"gmtCreate":1640186032395,"gmtModify":1640186032395,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691625975","repostId":"2193192429","repostType":4,"repost":{"id":"2193192429","kind":"news","pubTimestamp":1640185620,"share":"https://www.laohu8.com/m/news/2193192429?lang=&edition=full","pubTime":"2021-12-22 23:07","market":"us","language":"en","title":"Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’","url":"https://stock-news.laohu8.com/highlight/detail?id=2193192429","media":"Bloomberg","summary":" -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.These forces have thrown the broad investment outlook for the start of 2022 into flux, but what has","content":"<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.</p>\n<p>Shares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.</p>\n<p>These forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.</p>\n<p>The 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.</p>\n<p>“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”</p>\n<p>Netflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.</p>\n<p>Shares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.</p>\n<p>Cahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. <a href=\"https://laohu8.com/S/BPOPN\">Popular</a> content, subscriber growth and margin expansion -- the longstanding yardsticks for the company -- &nbsp;will remain the catalysts for shares, he said.</p>\n<p>“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”</p>\n<p><b>Fierce Competition</b></p>\n<p>For Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&amp;P 500 Index after buying shares in September.</p>\n<p>Netflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&amp;P 500 Communication Services Index at 19.6 times.</p>\n<p>Disney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.</p>\n<p>Both Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&amp;T Inc.’s WarnerMedia, according to <a href=\"https://laohu8.com/S/MQG.AU\">Macquarie</a> analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “<a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.</p>\n<p>But ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”</p>\n<p>“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.</p>\n<p><b>Buying Opportunities</b></p>\n<p>Selloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.</p>\n<p>Klink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.</p>\n<p>“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Netflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNetflix Rally in 2022 Hinges on Finding the Next ‘Squid Game’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-22 23:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with...</p>\n\n<a href=\"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4524":"宅经济概念","BK4532":"文艺复兴科技持仓","BK4527":"明星科技股","BK4551":"寇图资本持仓","BK4566":"资本集团","NFLX":"奈飞","BK4534":"瑞士信贷持仓","BK4108":"电影和娱乐","QNETCN":"纳斯达克中美互联网老虎指数","BK4548":"巴美列捷福持仓","BK4507":"流媒体概念","DIS":"迪士尼"},"source_url":"https://finance.yahoo.com/news/netflix-rally-2022-hinges-finding-120000844.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2193192429","content_text":"(Bloomberg) -- Fast-growing technology stocks have taken a beating in recent weeks -- and Netflix Inc. is no exception.\nShares of the streaming giant are down 13% from a Nov. 17 record, in tandem with the slump in the tech-heavy Nasdaq 100 Stock Index after the Federal Reserve indicated three rate increases and faster tapering in 2022. Concerns over the omicron coronavirus variant have also pressured equities.\nThese forces have thrown the broad investment outlook for the start of 2022 into flux, but what hasn’t changed is the bullish view on Netflix shares. Wall Street’s optimism hinges on the company’s ability to lure new subscribers with best-in-class content, boosting margins and cash flow along the way.\nThe 12-month average analyst price target comes in at $683, which implies a 13% gain from Tuesday’s closing price of $604.92. That’s less than the 28% increase analysts project for streaming rival Walt Disney Co., but it would extend Netflix’s streak of double-digit annual gains.\n“Despite market turbulence, we’re still interested in having exposure to tech companies,” said Erica Furfaro, senior portfolio analyst at ClearBridge Investments, which holds Netflix shares. “Even in a rising rate environment, being invested behind the best growth winners is still a prudent approach.”\nNetflix this year defied skeptics who fretted that it might stall as the world began to open up from lockdowns. After falling in the first half, the stock climbed to fresh highs on the unexpected success of South Korean show “Squid Game,” which became Netflix’s biggest series launch ever.\nShares had already started to climb in early August, with the stock riding a three-month, 33% rally as Wall Street began to appreciate the slew of shows and movies coming in the third and fourth quarters, including new seasons of “Money Heist” and “Sex Education,” said Wells Fargo Securities analyst Steven Cahall.\nCahall is among analysts that expect Netflix’s rally will continue, projecting that the stock will reach $800 by the end of 2022. Popular content, subscriber growth and margin expansion -- the longstanding yardsticks for the company --  will remain the catalysts for shares, he said.\n“All the revenue is based on content,” Cahall said in an interview. “The content is the majority of their costs. And so their ability to spend on content and generate new content is really what drives these business models.”\nFierce Competition\nFor Mark Stoeckle, chief executive officer and senior portfolio manager at Adams Funds, Netflix’s valuation and streaming competition are two factors that are keeping him from turning more bullish on the stock. The Adams Diversified Equity Fund is modestly overweight Netflix versus the S&P 500 Index after buying shares in September.\nNetflix trades around 46 times forward earnings. Although that’s down from a recent peak of nearly 54 times in October, it still tops the Nasdaq 100 at 28 times and the S&P 500 Communication Services Index at 19.6 times.\nDisney, whose flagship streaming service is widely seen as Netflix’s biggest competitor, has tumbled amid concerns that subscriber growth at Disney+ is slowing and as the variant threatens a return to theme parks. The stock is heading for its first annual decline since 2016 and its worst year since 2008.\nBoth Netflix and Disney face competition in 2022 from the direct-to-consumer service that will emerge from the merger of Discovery Inc. and AT&T Inc.’s WarnerMedia, according to Macquarie analyst Tim Nollen. Last month, he upgraded Discovery to outperform from neutral in anticipation of the deal which he said will create “one of the most broad-based content offerings.” He’s neutral on Netflix on valuation and rates Disney outperform based in part on an eventual rebound at its parks and the box office.\nBut ultimately, it’s nearly all about content, analysts say. The slate for 2022 includes new seasons for some of its biggest hits, including “Stranger Things” and “Bridgerton.”\n“I hate to say that these big media companies are just still in the hit business, but they are,” Cahall said.\nBuying Opportunities\nSelloffs are part of the equation, according to David Klink, senior equity analyst at Huntington National Bank, but he views them as buying opportunities for Netflix shares. Huntington Private Bank’s internal growth strategy added to its position in late November, he said.\nKlink had been worried that Netflix and other companies that were popular plays during Covid-19 lockdowns would struggle in 2021 as they faced tough year-over-year comparisons. Netflix proved those fears were overblown. It’s on track to notch a 12% advance for 2021 in what would be the stock’s seventh straight year of gains -- even with the most recent slump.\n“There’s rarely a year where there’s not a 10 or 15% drawdown, but you’re generally better off holding it,” Klink said.","news_type":1,"symbols_score_info":{"DIS":0.6,"NFLX":0.9,"QNETCN":0.9}},"isVote":1,"tweetType":1,"viewCount":1790,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626151,"gmtCreate":1640185863507,"gmtModify":1640185863507,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626151","repostId":"2193419144","repostType":4,"isVote":1,"tweetType":1,"viewCount":2500,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622121,"gmtCreate":1640185928643,"gmtModify":1640185971826,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622121","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":1568,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622066,"gmtCreate":1640185916183,"gmtModify":1640185916183,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622066","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohu8.com/m/news/1188142807?lang=&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<ul>\n <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-22 21:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>\n <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>\n <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>\n <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>\n <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>\n <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>\n <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>\n <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>\n <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AGCO":"爱科集团","PCAR":"帕卡","ED":"爱迪生联合电气","ALXO":"ALX Oncology Holdings","FDS":"辉盛研究系统","CGNT":"Cognyte Software Ltd.","CMRX":"Chimerix Inc.","BIIB":"渤健公司","NKE":"耐克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"ADGI":0.9,"AGCO":0.9,"ALXO":0.9,"BIIB":0.9,"CGNT":0.9,"CMRX":0.9,"ED":0.9,"FDS":0.9,"NKE":0.9,"PCAR":0.9}},"isVote":1,"tweetType":1,"viewCount":2245,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626406,"gmtCreate":1640185907845,"gmtModify":1640185907845,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089174425482880","authorIdStr":"4089174425482880"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626406","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":1365,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}